PCA3 long noncoding RNA modulates the expression of key cancer-related genes in LNCaP prostate cancer cells

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 11339-11348

  Lemos, Ana Emília Goulart ^a   Ferreira, Luciana Bueno ^b   Batoreu, Nadia Maria ^a   de Freitas, Paula Priscilla ^c,d   Bonamino, Martin Hernan ^a,d   Gimba, Etel Rodrigues Pereira ^d,e  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF PORTO   (Portugal)

^c Zona Oeste Estadual University   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Cancer related genes; Gene expression; Long noncoding RNA; PCA3; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CLAUDIN 3; CLAUDIN 4; CYTOKERATIN 18; CYTOKERATIN 8; LONG UNTRANSLATED RNA; PROSTATE CANCER ANTIGEN 3 LONG NONCODING RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; INTRACELLULAR SIGNALING; PCA3 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; GENETICS; HUMAN; MALE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84960105883     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5012-3     Document Type: Article

References (41)

1. De Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–8.
2. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975–9.
3. Clarke RA, Zhao Z, Guo A-Y, Roper K, Teng L, Fang Z-M, et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One. 2009;4:e4995.
4. Van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate. 2003;57:205–25.
5. Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 2012;12:507.
6. Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008;27:7180–91.
7. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.
8. Matuszak EA, Kyprianou N. Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis. Expert Rev Endocrinol Metab. 2011;6:469–82.
9. Li P, Yang R, Gao W-Q. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer. 2014;13:55.
10. Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Update Rev Comment Antimicrob Anticancer Chemother. 2008;11:123–51.
11. Nantajit D, Lin D, Li JJ. The network of epithelial-mesenchymal transition: potential new targets for tumor resistance. J. Cancer Res Clin Oncol. 2014.
12. Angrand P-O, Vennin C, Le Bourhis X, Adriaenssens E. The role of long non-coding RNAs in genome formatting and expression. Front Genet. 2015;6:165.
13. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013;500:598–602.
14. Bonamino M, Serafini M, D’Amico G, Gaipa G, Todisco E, Bernasconi S, et al. Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. Gene Ther. 2004;11:85–93.
15. Sung YY, Cheung E. Androgen receptor co-regulatory networks in castration-resistant prostate cancer. Endocr Relat Cancer. 2014;21:R1–11.
16. Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 1833;2013:3481–98.
17. Parolia A, Crea F, Xue H, Wang Y, Mo F, Ramnarine VR, et al. The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Mol Cancer. 2015;14:46.
18. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, et al. The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014;5:1434–8.
19. Yacqub-Usman K, Pickard MR, Williams GT. Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells. Prostate. 2015;75:693–705.
20. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, et al. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res. 2014;12:1081–7.
21. Wang L, Han S, Jin G, Zhou X, Li M, Ying X, et al. Linc00963: a novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. Int J Oncol. 2014;44:2041–9.
22. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015;112:8403–8.
23. Grabinski N, Ewald F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs. 2014;32:1096–104.
24. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira S-M, García-Echeverría C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 2009;106:268–73.
25. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, et al. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle Georget Tex. 2008;7:2553–61.
26. Wang C-M, Jia Z-J, Zheng R-L. The effect of 17 sesquiterpenes on cell viability and telomerase activity in the human ovarian cancer cell line HO-8910. Planta Med. 2007;73:180–4.
27. Li AJ, McAllister P, Karlan BY. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers. Gynecol Oncol. 2010;116:105–8.
28. Hammarsten P, Winther J, Rudolfsson SH, Häggström J, Karalija A, Egevad L, et al. ErbB2 receptor immunoreactivity in prostate cancer: relationship to the androgen receptor, disease severity at diagnosis and disease outcome. PLoS One. 2014;9:e105063.
29. Tillman K, Oberfield JL, Shen XQ, Bubulya A, Shemshedini L. c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation. Endocrine. 1998;9:193–200.
30. Liu L, Dong X. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells. PLoS One. 2014;9:e108780.
31. Papadopoulou N, Charalampopoulos I, Anagnostopoulou V, Konstantinidis G, Föller M, Gravanis A, et al. Membrane androgen receptor activation triggers down-regulation of PI-3K/Akt/NF-kappaB activity and induces apoptotic responses via Bad, FasL and caspase-3 in DU145 prostate cancer cells. Mol Cancer. 2008;7:88.
32. Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, et al. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. FASEB J Off Publ Fed Am Soc Exp Biol. 2008;22:1258–67.
33. Pentyala SN, Whyard TC, Waltzer WC, Meek AG, Hod Y. Androgen induction of urokinase gene expression in LNCaP cells is dependent on their interaction with the extracellular matrix. Cancer Lett. 1998;130:121–6.
34. Hung C-L, Wang L-Y, Yu Y-L, Chen H-W, Srivastava S, Petrovics G, et al. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci U S A. 2014;111:18697–702.
35. Wang D, Tindall DJ. Androgen action during prostate carcinogenesis. Methods Mol Biol. 2011;776:25–44. Clifton NJ.
36. Laschak M, Bechtel M, Spindler K-D, Hessenauer A. Inability of NCoR/SMRT to repress androgen receptor transcriptional activity in prostate cancer cell lines. Int J Mol Med. 2011;28:645–51.
37. Daniels G, Jha R, Shen Y, Logan SK, Lee P. Androgen receptor coactivators that inhibit prostate cancer growth. Am J Clin Exp Urol. 2014;2:62–70.
38. Liu Z, Hao C, Song D, Zhang N, Bao H, Qu Q. androgen receptor coregulator CTBP1-as is associated with polycystic ovary syndrome in Chinese women: a preliminary study. Reprod Sci. Thousand Oaks Calif. 2014.
39. Yang X, Bemis L, Su L-J, Gao D, Flaig TW. miR-125b regulation of androgen receptor signaling via modulation of the receptor complex co-repressor NCOR2. Biores Open Access. 2012;1:55–62.
40. Chao Y, Wu Q, Acquafondata M, Dhir R, Wells A. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron Off J Int Cancer Microenviron Soc. 2012;5:19–28.
41. Inge LJ, Barwe SP, D’Ambrosio J, Gopal J, Lu K, Ryazantsev S, et al. Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor. Exp Cell Res. 2011;317:838–48.